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The past fifty years have witnessed a “revolution” in global economic growth. Yet not everyone has participated in this revolution.
More than 65% of the world’s population, over four billion people, still lives on the equivalent of less than $4 per person per day.
Even worse, the world’s poor are severely constrained – and often completely lacking – in opportunity to do better for themselves.
The business community has both the capabilities and the strategic, business reasons to play a major role in creating these
opportunities. The CSR Initiative’s Economic Opportunity Series, a product of our Economic Opportunity Program, explores this role
across a range of industries.
For the poor, livelihood choices – in employment and entrepreneurship – are constrained by a
wide range of interdependent obstacles, ranging from geographic isolation to market failures to
political exclusion. This suggests that when we think about eradicating poverty, we should think
broadly about creating economic opportunity. Economic opportunity is not, in itself, a solution;
instead it is a context in which individuals can create their own solutions. It is a combination of
factors that enables the poor to manage their assets in ways that generate incomes and options.
Creating or expanding economic opportunity could rightly be considered a responsibility of governments toward their citizens. But in
today's global market environment, various risks and opportunities provide reason for business to engage.
One key reason, across industries, is for business to leverage its own comparative advantage in society. As Milton Friedman might
say, “the business of business is business” – and this is exactly what gives firms the capability and credibility to expand economic
opportunity. Business activity creates jobs, cultivates inter-firm linkages, enables technology transfer, builds human capital and
physical infrastructure, generates tax revenues for governments, and, of course offers a variety of products and services to
consumers and other businesses. Each of these contributions has multiplier effects on development.
In developing countries, companies’ multipliers often fail to reach the scale or leverage of which they might be capable – often due
to market failures and governance gaps. More deliberate management attention is required to unlock their full potential.
The Economic Opportunity Series explores four key strategies companies can use to expand economic opportunity:
Creating Inclusive Business Models Involving the poor as employees, entrepreneurs, suppliers, distributors,
retailers, customers, and sources of innovation in financially viable ways
Developing Human Capital Improving the health, education, experience, and skills of employees, business
partners, and members of the community
Building Institutional Capacity Strengthening the industry associations, market intermediaries, universities,
governments, civil society organizations, and grassroots groups who must all
be able to play their roles effectively within the system
Helping to Optimize the “Rules of the Game” Shaping the regulatory and policy frameworks and business norms that help
determine how well the economic opportunity system works, and the extent to
which it is inclusive of the poor
Preface
Beth Jenkins, CSR Initiative, Kennedy School of Government, Harvard University
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“Economic opportunity
enables people to
manage their assets in
ways that generate
incomes and options.”
There is enormous variation in the roles companies can play, depending on their industries, their particular business models and
relationships, and the contexts in which they operate. The industry reports in the Economic Opportunity Series explore this variation,
offering more specific and detailed examples for different industry sectors. The research suggests, in general, that inclusive business
models can be the most effective and sustainable ways companies can contribute. Complementary strategies such as developing
human capital, building institutional capacity, and helping to optimize the “rules of the game” can also have significant impacts.
These strategies are often used in combination with inclusive business models, to enhance both their commercial viability and
theirdevelopment impact.
The research that has gone into this series also suggests that company efforts to expand economic opportunity can draw upon core
business, philanthropic, and public donor funding, depending on the balance of business and social benefits expected, the likely
timeframe for their realization, and the level of uncertainty or risk involved. Hybrid approaches are increasingly common.
So is collaboration. Complex, systemic challenges like expanding economic opportunity present frustratingly frequent bottlenecks to
unilateral action, corporate or otherwise. Even the best-resourced efforts eventually run into limitations on scale somewhere.
Collaboration allows parties to share knowledge and information, pool scarce or diverse assets and resources, access new sources
of innovation, create economies of scale, and enhance the legitimacy of the parties’ own individual activities. In addition to
assembling the necessary resources and capabilities, collaboration can generate new capabilities and change operating
environments in ways that create new strategic opportunities.
The Economic Opportunity Series is part of a growing effort within the business and development communities to make the links
between business activity and poverty alleviation. Experimentation and learning are happening fast. As a result, the series must be
considered a work-in-progress, and readers are invited to share their experience and reflections with us. We look forward to being
part of the dynamic growth and development occurring in this field.
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 Executive Summary
Multinational health care companies can play critical roles not only in improving access to medicines and
quality care for citizens of developing countries, but also in expanding economic opportunities in those
countries. While the health care industry broadly defined includes a wide range of businesses, for the purposes
of this paper, we have focused on the pharmaceutical industry and the ways it can participate in expanding
economic opportunity in developing countries.
Compared to many other industries, the pharmaceutical industry is unique in the ways it creates economic
opportunity. First, because many parts of the pharmaceutical value chain require only a small number of well-
educated workers, the industry is typically not well positioned to directly provide large-scale employment in
developing countries. In addition, the markets that multinational pharmaceutical companies target for their
products are fairly limited in developing countries, and this restricts the scale of employment in those markets.
Finally, the core competencies of pharma companies lie in expanding access to medicine and health care. The
majority of their efforts in the developing world focus on these issues through activities such as drug donation
and patient assistance programs. While these programs may not always lead directly to expanded economic
opportunity, they help lay the foundation for it by improving public health, an essential enabling condition
for individual productivity and overall economic development.
Companies can consider a number of motivations and risks when determining how deeply or deliberately to
engage in expanding economic opportunity. Motivations include the possibility of creating competitive
advantage, increasing operational efficiencies, and enhancing philanthropic impact, while risks include
reputational risk and regulatory risk related to intellectual property rights and counterfeit drugs.
Currently, pharma companies engage in a variety of economic opportunity strategies through both their
business and philanthropic activities. This paper organizes the industry’s initiatives into three tiers of activity
based on their potential for impact.
1. Creating Inclusive Business Models: Inclusive business models are the “strategic cornerstones” for action to
expand economic opportunity due to their potential for developing local businesses and creating new highly-
skilled jobs. For pharma companies, inclusive business models incorporate a range of activities such as foreign
direct investment, or establishing a local presence in developing countries; technology transfer or voluntary
licensing agreements; and incorporating local businesses into the company’s value chain through sourcing of
raw materials or outsourcing services such as information technology.
2. Capacity-Building Initiatives: While capacity-building activities do not always lead directly and immediately to
new jobs, they have the potential for significant impact in developing countries, where educational and
professional training opportunities are limited and local infrastructure systems are often weak. By helping train
workers and strengthen local institutions, these activities act as precursors to expanding economic opportunity.
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3. Rule-Shaping Activities: Companies can help shape the “rules of the game” that affect the extent of economic
opportunity available by influencing changes in public policy or regulation that lead to job creation or foster
better business environments. These activities, while often longer-term in nature, can lead to large-scale
economic impact in developing countries.
The examples highlighted in this paper demonstrate that companies have pursued a broad range of initiatives
with various business and philanthropic goals, representing a range of potential for economic opportunity
impact. There is no single right way to engage in expanding economic opportunity in developing countries;
multiple opportunities to contribute exist and each company’s strategy will depend on its business objectives,
competitive advantages, and corporate social responsibility or philanthropic goals.
Our research has identified three major themes for companies to consider going forward.
1. Engage in Rule-Shaping: Pharmaceutical companies’ greatest opportunity to achieve large-scale impact is
through activities aimed at optimizing the “rules of the game.” Such activities, while long-term in nature,
create the foundation for increased economic opportunity by establishing the conditions that attract business
and generate job creation. However, while rule-shaping offers a compelling opportunity for pharmaceutical
companies to achieve both social and business impact, the incentives for Western pharma companies to
engage in these activities may be limited in the very near term given the current size of the market in
developing countries.
2. Track and Communicate: Our research has identified a lack of emphasis on identifying, tracking, and
communicating the economic impact of pharma companies’ current activities. Undertaking simple measures
to track economic opportunity impact – even when programs are focused on other outcomes – can provide
the industry with the opportunity to highlight its economic footprint without the need for additional large
investments. Communicating about economic benefits also allows the industry to supplement its messages
about the value it brings to society, beyond health care.
3. Collaborate to Maximize Impact: Finally, collaboration within and outside the industry can play a significant role
in multiplying the impact of pharma companies’ economic opportunity strategies. While not all activities lend
themselves equally to collaboration, many of the examples highlighted in this paper feature successful
partnerships. These arrangements allow partners to focus on their respective comparative advantages to increase
impact, share risks, and increase the credibility of the efforts with other important stakeholders.
As pharmaceutical companies become more involved in both business and philanthropic activities in
developing countries, it will be important for each company to identify the best strategies available to it to
create new economic opportunities and to leverage the benefits of activities already underway. While the
primary focus of the industry is, and will most likely continue to be, on increasing access to health care, the
potential for expanding economic opportunities through its activities should not be overlooked as a
significant outcome.
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1  The Role of the Health Care Industry
Multinational health care companies can play critical roles not only in improving access to medicines and
quality care for citizens of developing countries, but also in expanding economic opportunities in those
countries. While the major focus of health care companies is to provide access to health services and medicines,
they also contribute to expanding economic opportunities through job creation, training and capacity-
building, and shaping public policy.
The health care industry broadly defined
includes a wide range of businesses: drug
manufacturers, including pharmaceuticals and
biotechnology; diagnostics and device manu-
facturers; hospitals; insurance providers; and
health technology and information providers.
For the purposes of this paper, we have focused
on the pharmaceutical industry and the ways it
can participate in expanding economic
opportunity in developing countries. While
other actors in the health care sector can be
important contributors to economic opportunity
as well, the resources that large pharmaceutical
companies can harness – their multinational
reach, relationships with governments, and
enormous potential for financial value creation –
offer unique opportunities for social impact in
the developing world.
It is also important to note that while this paper focuses on multinational companies in the pharmaceutical
industry, local businesses in developing countries can also have powerful impacts in creating economic
opportunities. Due to their very location, these local companies employ thousands of citizens of developing
countries. More importantly, in recent years several developing world generics manufacturers have rapidly
expanded operations to countries around the world. As a result of their global operations, these companies
have been able to increase production and create new and better-paying jobs in their home countries. For
example, the Indian generics manufacturer Ranbaxy operates in 49 countries and employs 2,500 people in
India.1 While not a focus of this paper, many of these companies are in fact multinational in nature and provide
significant economic opportunities.
Compared to many other industries, the pharmaceutical industry is unique in the ways it creates economic
opportunity. First, the core competencies of pharmaceutical companies lie in expanding access to medicine
BOX 1 OTHER PLAYERS IN THE HEALTH CARE SECTOR
Other companies within the health care sector, such as insurance
providers and hospital chains, offer the potential to create large-scale
economic opportunities in developing countries. These companies can
often employ large numbers of local citizens at different positions
(health care providers, managerial staff, support staff) with varying
degrees of skills and training. Their operations also contribute to
creating clusters of economic activities formed around various
supporting industries, such as information technology and financial
services, catering, medical equipment supplies, and so on. However, our
research did not identify major multinational chains in these industries
that were operating in developing markets. Weak demand conditions
and government provision of health care in developing countries may
help explain this gap. While it may still take several years for
multinational insurance or hospital chains to appear, the economic
opportunity potential of these companies remains high.
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and health care. It is not a coincidence that the vast majority of activities undertaken by pharma companies
in the developing world are related to these core competencies. While drug donation or patient assistance
programs may not always lead directly to economic opportunity, access to health is essential to creating the
necessary conditions for economic development across all industries.2 Jane Nelson, Director of the Corporate
Social Responsibility Initiative at Harvard University, observes, “Unhealthy workforces and weak public
health systems, especially in situations where HIV/AIDs and other diseases are widespread, often result in
lower productivity, increased absenteeism and staff turnover, loss of skills, increased costs, and declining
profits and investments.”3
It is extremely important, therefore, that pharma companies continue these activities, given the industry’s
specific skills, resources, and expertise, and the impact on health outcomes resulting from these programs.
Klaus Leisinger, President of the Novartis Foundation for Sustainable Development, comments on the role of
the industry’s involvement in tackling social challenges: “It is advisable that companies become engaged in the
sectors where their core competence lies and not in general social or other issues – e.g., pharma companies
should choose engagements in the health sector.”4
Second, compared to many other industries, many parts of the pharmaceutical industry value chain in
developing countries are not extremely labor intensive.5 The staff employed in this industry require a
certain level of education and training, and often, specialized expertise for jobs that involve scientific
discovery, regulatory affairs, and medical marketing. In contrast to industries such as food and beverage or
hospitality, job creation by pharma companies in developing countries does not usually focus on the very
poor, who are often less educated. Reeta Roy, Vice President of Abbott Fund and Divisional Vice
President, Global Citizenship and Policy at Abbott Labs, comments, “Given the types of research and
manufacturing jobs we have, we’d clearly go after an educated, well-informed population. Our target
group is fairly small.” Stavros Nicolaou, Senior Executive at the South African pharma company Aspen
Pharmacare, noted the limitations of individual pharma companies in creating large-scale impact: “The
pharmaceutical industry isn’t labor intensive the way the textiles industry is, for example. We have
employed more people [in the past few years], but when you have a 30% unemployment rate, ours is not
a major absorption effort. The larger benefits lie elsewhere, such as ensuring supply security, improving
sub-Saharan Africa’s balance of payments and bridging Africa’s escalating pharmaceutical trade imbalance,
and enabling domestic players to become meaningful players in the growing infectious disease market.”
In addition, the markets that multinational pharmaceuticals target for their products are also fairly limited
in developing countries. While many Western firms provide drug donations and discounted prices, and
local generics manufacturers have also increased access in developing country markets in recent years,
branded pharmaceutical drugs still remain out of reach for the majority of developing country citizens. The
small market size for their products in developing countries also influences pharma companies’ scale of
employment across their value chains in those markets.
Therefore, both because of the nature of the business and the industry’s workforce needs, most pharma
companies’ philanthropic and value chain activities are not explicitly focused on creating economic
opportunity; rather, they focus on creating access to medicine and health care. Economic opportunity,
however, is often an important by-product of these efforts. “The primary goal of our philanthropic
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activities is improvement in the provision of health care for the local population and improved access
to our medicines. While not the main objective of our activities, the creation of economic opportunities
in the form of jobs is a positive by-product,” comments Sebastian Fries, Director of Strategic Planning
for Africa, Middle East, and Latin America at Pfizer.
Given the industry’s focus on health, it is perhaps not surprising that few companies appear to track or measure
their direct contributions towards expanding economic opportunity. In spite of several examples of successful
philanthropic programs or value chain activities that have created economic opportunity, most companies do
not communicate about the opportunities created by their efforts. Furthermore, only a handful of the large
pharma companies mention economic development specifically on their websites or in their citizenship
reports. Our research has identified opportunities for pharmaceutical companies to not only expand their roles
in developing countries, but also to leverage the economic impact of their existing efforts in those markets.
Novo Nordisk, for example, has developed an “economic footprint” model and illustrates on their website the
direct and indirect impact the company has on economic activities in developing countries.6
Methodology
This paper’s research methodology applies the results of primary and secondary research to a strategic
framework. Due to limitations on time, scope, and space, the sample size of companies interviewed for the
paper is small, and the authors acknowledge that the research may omit some companies that deserve to be
profiled. The primary research for the paper draws on phone interviews with 11 experts representing
multinational pharmaceutical corporations, locally-based pharmaceutical companies, and an industry trade
group (see Appendix A, List of Companies Interviewed). The phone interviews focused on developing an in-
depth understanding of approaches to increasing economic opportunity and lessons learned through these
activities. Secondary research included a review of relevant reports, studies, and articles from a range of sources
on the subject of corporate responsibility and economic opportunity.
The findings of this paper are divided into three primary sections. The first section provides an overview of
the value of engagement for pharma companies in expanding economic opportunity in developing countries.
It also identifies the risks associated with minimal participation in these activities. The second section presents
a strategic framework developed by the authors to depict the different strategies large pharmaceutical
companies can employ in developing countries. The third section outlines potential roles for the industry to
play in expanding economic opportunity in the future. Finally, the fourth section provides case studies
profiling the strategies employed by several pharmaceutical companies.
We hope that the discussion and findings provide ideas that will lead pharmaceutical and other health care
companies to make more deliberate strategic investments that will enhance economic opportunities for citizens
of developing countries.
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2  The Value of Engagement
What incentives exist to encourage pharmaceutical companies to increase their engagement in expanding
economic opportunities in developing countries? As discussed, most major pharmaceutical companies already
administer extensive drug donation programs and other initiatives aimed at improving access to health care
in developing countries – primarily as part of their philanthropic initiatives. Together, for example, the seven
companies profiled in this paper donated products valued at over $4 billion in the most recent year for which
data are available.7 So what is the business case for increasing involvement in these countries?
Companies can consider a number of motivations and risks when determining how deeply and deliberately
to engage in expanding economic opportunity. For pharmaceutical companies, motivations include the
possibility of creating competitive advantage, increasing operational efficiencies, and increasing the impact of
philanthropic activities in developing countries. Potential risks include reputational risk and regulatory risk
related to intellectual property rights and counterfeit drugs.
2.1 Motivations: How Companies Benefit
2.1.1 Creating Competitive Advantage
A key incentive for companies to engage in activities that create economic opportunity is the potential to create
competitive advantage. This is particularly true in key emerging markets, such as China, India, Brazil, South
Africa, and Russia, where the near-term prospect of increased sales and revenue makes local investment an
attractive opportunity. Companies’ economic opportunity activities can assist them in entering new markets
through fostering relationships with key stakeholders and demonstrating a commitment to the local community.
Merck’s competitiveness initiative, for example, has helped the company gain access to government leaders in
Mexico and Brazil and has positioned it as a partner of choice for future collaborations with local governments,
businesses, and civil society groups. Even in other developing countries, creating competitive advantage can serve
as a motivation for companies to engage in economic opportunity activities. Peter Gerhardsson of Novo Nordisk
comments, “There is a very strong will for us to engage in poorer countries. Our interventions help these
countries, and in the long run they help our market potential in those countries as well.”
2.1.2 Increasing Operational Efficiencies
Economic opportunity activities in developing countries can also help companies achieve operational
efficiencies through streamlining drug production and distribution processes for products that are widely
used in those markets. For example, Sanofi-Aventis recently transferred all production of a rifampicin-based
drug used to treat tuberculosis from a site in Italy to a site in South Africa. This decision was motivated by
several factors: first, it moved production closer to the areas where rifampicin-based drugs are used; second,
it allowed Sanofi-Aventis to lower its production cost for each treatment by about 35%; and third, it
bolstered the sustainability of the South African facility by strengthening the site’s tuberculosis expertise and
increasing manufacturing activity there.
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Companies can also increase operational efficiencies through local sourcing practices that have a significant
positive impact on local economies. Sourcing of raw materials from developing countries, while not a
widespread practice, also offers an opportunity for increased operational efficiency. Novartis, for example,
developed a partnership with the Kenya-based company East African Botanicals (EAB) in order to expand
production of an active ingredient in its antimalarial drug Coartem®. Coartem® is the only fixed-dose
Artemisinin-based Combination Therapy (ACT) pre-qualified by the WHO for procurement by United
Nations agencies, and has been adopted as the first-line defense against malaria in dozens of countries in Africa.
These conditions created significantly increased demand for the product between 2003 and 2005. Developing
a partnership with EAB enabled Novartis to meet the demand for its drug while also permitting EAB to
provide supply contracts to several thousand local farmers in Kenya and Tanzania.
Finally, companies can outsource different parts of their value chain to smaller firms based in developing
countries. Such arrangements enable multinational companies to keep their production costs down while
providing growth opportunities for locally-based companies and expanding economic opportunities for
citizens in developing countries. Pfizer, for example, has contracted with the Malaysian drug company,
Pharmaniaga Manufacturing Berhad, since 1991 to lower costs associated with manufacturing tablets.
2.1.3 Increasing Philanthropic Impact
In many developing countries where pharma companies engage in philanthropic activities, economic
opportunity engagements can help improve companies’ ability to achieve their philanthropic goals. Activities
that lead to increased economic opportunity, such as collaborating with local organizations, can improve the
efficiency and effectiveness of philanthropic activities by expanding capacity, reducing transaction costs and
time requirements, catering to local needs, and involving local citizens in developing health solutions.
For example, Lilly provided technology transfer for its capreomycin (Capastat®) and cycloserine (Seromycin®)
drugs to Aspen Pharmacare, the South African company, when it was discovered that those drugs are effective
in treating Multi-Drug Resistant Tuberculosis (MDR-TB). Though Lilly made investments to expand supply
of the drugs, it could not meet the growing demand alone. Providing technology transfer to Aspen Pharmacare
enabled Lilly to meet increased demand for its products in an efficient and cost-effective manner that also
expanded economic opportunities for South Africans. “Now that we’ve transferred the technology to [Aspen
Pharmacare], and have enhanced their capabilities through training, they now have additional opportunities
to produce other products that will be in compliance with Good Manufacturing Practices,” says Gail Cassell,
Vice President for Scientific Affairs and Distinguished Research Scholar for Infectious Diseases at Lilly. While
the primary motivation for the partnership was the reduction of TB instances, the partnership resulted in both
new jobs and an effective program that advances Lilly’s philanthropic goals in the region.
2.2 Risks: What Companies Stand to Lose
2.2.1 Reputational and Relationship Risk
One of the most significant drivers of companies’ engagement in developing countries is the reputational risk
they face if they do not fulfill the social obligations placed on them by multiple stakeholders. Companies have
experimented with several approaches to managing the tension that exists between the fundamental business
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model of the pharmaceutical industry – in which companies rely on profits from patented products to fund
significant investment in new research and development – and the needs presented by millions of people across
the globe who suffer from treatable diseases but lack the ability to pay for needed medicines. Almost all major
pharmaceutical companies, for example, administer extensive drug donation programs in Latin America,
Africa, and Asia. Nonetheless, pharmaceutical companies continue to face tremendous pressure from various
stakeholders, including consumers, advocacy organizations, and even shareholders, to do more to increase
access to medicines and basic health care services. By taking a proactive approach to increasing economic
opportunity in developing countries, pharmaceutical companies do not just minimize their reputational risk;
they can actually help improve their public image by demonstrating their commitment to improving the lives
of poor people in those countries. While pricing and intellectual property rights remain contentious issues,
generating good will in these countries can help the industry protect its basic business model by showcasing
the positive social impact it creates. Finally, partnership activities that expand economic opportunities allow
pharmaceutical companies to develop and strengthen relationships with key external stakeholders – a major
priority for the industry.
2.2.2 Regulatory Risk
Companies that do not engage in policy discussions related to intellectual property laws, laws governing the
production and distribution of counterfeit drugs, and other laws related to drug regulations risk becoming
constrained by the establishment of hostile business environments in developing countries. In 2006, for
example, the WHO estimated that there were several countries in Africa, Asia, and Latin America where more
than 30% of the medicines on sale could be counterfeit, in comparison to a rate of less than 1% in
industrialized countries with robust and effective regulatory systems and market control.8 Increased
involvement by pharmaceutical companies in shaping the “rules of the game” related to drug regulation and
penalties for counterfeiting helps address a serious public health concern. In addition, stronger anti-counterfeit
rules and their enforcement may induce further investment by the pharmaceutical industry in developing
countries. While “rule shaping” activities are an indirect and long-term strategy for creating economic
opportunity, Western pharmaceutical companies are well positioned to engage effectively in these activities.9
By leveraging their government influence, pharma companies can contribute to the establishment of better
business environments that will drive both local economic expansion and foreign investment.
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3  Economic Opportunity Strategies
3.1 Three Tiers of Activity to Increase Economic Opportunity
Our research has shown that large pharmaceutical companies engage in a variety of economic opportunity
strategies in developing countries. However, as stressed above and highlighted in the case studies, these
strategies are not typically employed with the explicit goal of creating economic opportunity. Rather, the
strategies are often incorporated into corporate initiatives aimed at a host of business and philanthropic goals,
including increased operational efficiency, increased market share, improved strategic positioning, improved
business environment, and expanded access to health care for citizens of developing countries. Many of these
initiatives often contribute to increased economic opportunity, even though that is not their primary objective.
The strategies employed by multinational pharmaceutical companies can be organized into three tiers based
on how directly they contribute to increased economic opportunity for citizens in developing countries. The
first tier, which contributes most directly to increased economic opportunity, is Creating Inclusive Business
Models. Activities in this tier tie business activity to increased economic opportunity through the creation of
new or higher-skilled jobs and the expansion of local businesses. The second tier of activity is Capacity-
Building aimed at individuals and institutions. Capacity-building activities are a less direct form of economic
opportunity expansion because they usually do not lead immediately to job creation; however, they are
important in the context of developing countries, where educational and professional training opportunities
are often limited, and institutions often weak. The third tier of activity, Rule-Shaping, is the most indirect
form of economic opportunity expansion because its impact is long term and does not directly affect individual
workers. However, these activities help to create large-scale impact by helping to optimize the legal and
regulatory environments in which businesses in developing countries operate.
3.1.1 Tier One: Creating Inclusive Business Models
As outlined in the introduction, inclusive business models are the “strategic cornerstones” for action to expand
economic opportunity. For pharmaceutical companies, inclusive business models incorporate a range of
activities, such as:
• Foreign direct investment (FDI), or establishing a presence in developing countries to employ people at
their own facilities;
• Technology transfer or voluntary licensing agreements that allow local generic drug manufacturers to
produce drugs they otherwise would not be able to; and
• Incorporating local businesses into the company’s value chain through sourcing raw materials or
outsourcing other services, such as information technology.
These business activities directly contribute to the creation of new, often higher-skilled and better-paying jobs,
and enable local businesses to expand their operations and strengthen their financial positions. Roche
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Pharmaceuticals, for example, recently granted a license to Universal Corporation Limited in Kenya to
produce the generic equivalent of saquinavir, an Antiretroviral Therapy (ARV). The agreement highlighted
Roche’s role in expanding access to ARV treatments and also contributed to expanding economic opportunity
in Kenya, where Universal’s new $10-million plant employs 280 people.
While inclusive business models offer the most direct opportunity to create economic opportunity, the nature
of the pharmaceutical industry value chain limits the impact a single company can achieve utilizing this
approach. Due to the complex procedure of drug manufacturing, the process requires high-skilled employees
in relatively small numbers. The need for higher skilled employees prevents direct recruitment aimed at the
very poor, who are often less educated. The Roche example above underscores this limitation of the
pharmaceutical industry in the creation of large-scale employment opportunities. “We’re not best suited to
creating a lot of local manufacturing jobs. We’re not a labor intensive industry,” says Jon Pender, Director of
Government Affairs at GlaxoSmithKline. While direct investment in setting up facilities may not often involve
extensive collaboration, the other activities in this tier often involve collaborating with in-country partners.
3.1.2 Tier Two: Human and Institutional Capacity-Building
The second tier of activities that expand economic opportunity in developing countries focuses on building local
institutional and human capacity. While all major pharma companies engage in training or capacity-building
activities in developing countries, we have highlighted here a small subset of those programs. For example,
although not detailed in this paper, many drug donation programs incorporate training.
Human capacity-building programs may not always lead directly and immediately to new jobs, but they have
the potential for significant impact in developing countries, where educational and professional training
opportunities are limited and local infrastructure systems are often weak. By providing the necessary training
for acquiring better jobs or the institutional capacity to create new ones, these activities are often precursors to
expanding economic opportunities.10 While the majority of capacity-building activities highlighted in this paper
are carried out as part of the philanthropic activities of pharma companies, training activities are also carried out
through companies’ business practices. For example, pharma companies’ clinical trial efforts in developing
countries contribute to capacity-building and increased economic opportunity. Training and capacity-building
activities also involve high levels of collaboration, usually with non-profit partners in the recipient developing
countries.
Most multinational pharmaceutical companies are actively engaged in human capacity-building initiatives
targeting physicians, nurses, community health workers, and other vocational health care workers. Pfizer,
Abbott, GSK, and Novo Nordisk, for example, all fund several training programs to increase the number of
highly skilled and knowledgeable health care workers in countries across Africa and Asia. Abbott’s HIV/AIDS
program in Tanzania, for example, has trained over 10,000 professional and community-based health care
workers in HIV care and treatment, counseling and testing, equipment operation, and hospital management
since its launch in 2001. GSK’s Thai Nursing program is another example that has graduated 500 nurses in
five years and has provided critical training in primary care, prevention, and disease management to women
who may otherwise have ended up in prostitution. Training programs help already-employed professionals
access better-paying jobs and can also position unskilled workers for new jobs they may not have previously
qualified for. Thus, while these activities may be less direct, human capacity-building programs achieve impact
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on a larger scale than individual business operations by creating a cadre of trained health-care workers who
move on to employment across the entire health sector of a country.
Pharmaceutical companies are also engaged in helping to build local institutional capacity through providing
a variety of resources, including technical assistance, strategic planning advice, financial support, mentoring,
and networking assistance. These activities help contribute to the development of robust health care
infrastructure systems, which can then employ more local staff and increase access to health care services for
citizens. Strong infrastructure systems also help facilitate companies’ ability to access new markets and increase
distribution of products and services in existing markets. For example, the work of the International
Federation of Pharmaceutical Manufacturers and Associations (IFPMA) to increase developing country
capacity for drug registration and regulation will likely result in job creation and higher pay for regulatory
workers, and will expedite the review and approval processes for new drugs in those markets. Such activities
impact both individual job creation and the business constraints for pharmaceutical companies.
3.1.3 Tier Three: Helping to Optimize the “Rules of the Game”
The final category of activities in creating economic opportunity includes influencing changes in public policy
or regulation that lead to job creation or foster better business environments. By shaping the “rules of the
game,” these activities can lead to large-scale economic impact over time. Due to the long-term and often
complex nature of affecting public policy, these activities require strong partnerships with local champions and
other companies. For example, Merck’s Competitiveness Initiative for Latin America works with local non-
profit and business partners to promote competitiveness in Latin America, with an emphasis on projects that
support the development of the life sciences sector. Over the long term, the initiative will contribute to
enhanced economic opportunity by helping develop business cases, policies, and incentives that will drive the
development of new life sciences clusters in the region.
Shaping the “rules of the game” is the most indirect way through which to increase economic opportunity;
however, the potential for pharma companies to have economic opportunity impact is probably greatest in this
area. Significant opportunities for business impact also exist. For example, through working with governments
and regulatory agencies to address the problem of counterfeit drugs – a key business constraint for the
pharmaceutical industry – companies can help create a healthier business environment with strong property
rights and rule of law. The better business environment offered in these countries may encourage more
companies to establish local offices or forge partnerships with local firms. For example, GSK’s decision to
partner with Aspen Pharmacare was driven in part by the existence of a relatively robust drug regulation
infrastructure in South Africa, as well as by Aspen’s reputation for respecting international intellectual property
laws. Our research also indicates that rule-shaping is an area where few pharmaceutical companies are actively
engaged, providing an opportunity for high impact and differentiation.
3.2 Reinforcing Activities
While direct engagement of pharmaceutical companies in developing countries through local employment,
local procurement, and local sales is the most direct way of expanding economic opportunity, two critical
conditions must first be in place to facilitate this form of engagement. First, prospective employees must
possess the level of knowledge and skills required for success in the newly-created positions. For the health care
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industry in particular, human capacity-building is therefore an important complementary strategy to the
strategic cornerstone of creating inclusive business models. Second, the laws, regulations, and tax incentives in
place in developing countries must create an enabling environment that is supportive of inclusive business
models. Complementary rule-shaping activities that optimize the “rules of the game” are crucial in this regard.
Together, the three tiers of activity reinforce one another and form a more comprehensive approach to
expanding economic opportunity in developing countries.
3.3 Mapping Economic Opportunity Strategies
The framework pictured in Figure 1 provides a visual depiction of the three tiers of pharmaceutical industry
activity that lead to economic opportunity in developing countries. As discussed, the first tier represents the
most direct way for companies to expand economic opportunity, while activities in the second and third tiers
contribute more indirectly to expanded opportunity.
The size of each tier of activity within the framework is representative of the potential impact of that activity.
Although inclusive business models contribute directly to the creation of new jobs and expanded economic
opportunity, they typically have limited impact due to the nature of employment needs within the
pharmaceutical industry. The inclusive business model tier is therefore the smallest of the three. Capacity-
building initiatives, which comprise the middle tier, offer more indirect opportunities to expand economic
opportunity, but often reach more people than individual business operations. Finally, rule-shaping activities
that target the overall environments in which businesses operate, while most indirect, comprise the largest tier,
representing pharma companies’ greatest opportunity for impact.
In addition to illustrating the different types of activity, their relationships to one another, and the relative scale
of their impacts, the framework also distinguishes between activities that are motivated by companies’ business
interests and those that are motivated by their philanthropic goals. Finally, the framework maps individual
activities undertaken by the companies profiled in this report across these three tiers.
FIGURE 1 THE THREE TIERS OF ACTIVITIES THAT EXPAND ECONOMIC OPPORTUNITY
Note: The positioning of individual companies within the framework reflects the authors’ interpretations of the highlighted programs. Companies may be engaged in
additional activities in other tiers beyond what is depicted in the framework.
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A company’s motivation to engage in economic opportunity is shaped by the nature of the challenge being
addressed, the market potential of the target country, and the presence of internal support or champions within
the company. Motivation also influences where the initiative is housed within the company. When activities are
critical to the operations of pharmaceutical companies in developing countries, they are often best handled by the
business units. Novartis’ decision to partner with EAB in Kenya to ensure adequate supplies of a key ingredient
in Coartem® is one such example. AstraZeneca represents a second example, with more than 300 local citizens
employed in its two research and development facilities in Bangalore, India. Many of the training activities
currently operating in developing countries, on the other hand, are undertaken by the companies’ philanthropic
or corporate contributions units. Occasionally, initiatives are located or managed within one unit of a company
but heavily utilize the resources available in other units to ensure successful implementation. For example, Lilly’s
technology transfer initiative is part of its philanthropic MDR-TB partnership, but takes advantage of the skills
and expertise of Lilly employees in the business units.
As expected, most of the inclusive business models we researched fall within companies’ business units (the
technology transfer initiative at Lilly is an exception). Each of these initiatives has a direct, but limited impact on
economic opportunities in developing countries. Of the second tier of activities, the human capacity-building
programs we researched are all run through companies’ philanthropic units, likely due to the fact that they are
part of larger initiatives designed to bolster local public health systems.11 Because most of the training programs
last from three to six months, they are able to target several hundred citizens over the course of a few years.
Additionally, because all of the programs in this tier are also highly collaborative, relying on the engagement of
local non-governmental organizations to help design and implement effective programs, the initiatives allow
sponsoring companies to build relationships with local stakeholders.
IFPMA’s institutional capacity-building initiative aims to strengthen government regulatory capacity through training
regulatory and clinical trial workers. The initiative is run through the Partnership Taskforce, comprised of business
representatives from several IFPMA member companies. The initiative has only just begun, so impact assessments are
not available. However, if successful, the effort to expand in-country capacity for clinical trials and expand quality
assurance and drug regulation programs is likely to result in the creation of jobs across the continent of Africa.
Finally, in rule-shaping, Merck’s Competitiveness Initiative relies on the collaboration of industry and government
partners to spark innovation and drive the development of business clusters in Latin America. It is housed within
Merck’s business unit rather than its philanthropic unit, reflecting the strategic relevance of the initiative to Merck’s
future business interests in the region. While this is a long-term project, its ultimate impact on the business
environment and economic opportunities available in Latin America could be significant.
Our research highlights companies that have pursued economic opportunity initiatives with various business and
philanthropic goals, representing a range of potential for impact. There is no single right way to engage in
expanding economic opportunity in developing countries; multiple opportunities to contribute exist and each
company’s strategy will depend on its business objectives, competitive advantages, and corporate social
responsibility or philanthropic goals. Our research indicates, however, that pharma companies’ greatest
opportunity to achieve large-scale impact is through activities aimed at optimizing the “rules of the game.” Such
activities, while long-term in nature, establish the foundation for increased economic opportunity by creating the
conditions that attract business and generate job creation.
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4  Future Opportunities
Our research has identified three major themes for pharmaceutical companies to bear in mind as they engage
in future activities in developing countries.
1. Engage in Rule-Shaping: While inclusive business models offer the most direct method of creating economic
opportunities through the creation of jobs, companies’ greatest opportunity to achieve large-scale impact is
through activities aimed at optimizing the “rules of the game.” Such activities, while long-term in nature,
create the foundation for increased economic opportunity by establishing the conditions that attract business
and create jobs. A single pharma company’s expansion, even on a relatively large scale, typically results only in
a few hundred new jobs. On the other hand, changing the business environment in a developing country to
encourage organic growth of local businesses or to attract multiple foreign firms can result in thousands of new
jobs. In spite of the potential for impact, our research identifies a potential gap in participation in this third
tier of activities – not many pharmaceutical companies are playing active roles in creating economic
opportunity through rule-shaping. Both because of the potential for impact, and because of the opportunity
to take a leadership role in a relatively less crowded space, rule-shaping offers a compelling opportunity for
pharmaceutical companies to achieve both social and business impact. At the same time, given currently small
market sizes, the incentives for Western pharma companies to engage in rule-shaping in many developing
countries may be limited in the very near term.
One promising opportunity is offered by the recently founded Medicines Transparency Alliance (MeTA),
a partnership among the UK Department for International Development (DFID), the World Health
Organization, and several pharmaceutical companies and non-profit organizations that aims to increase
transparency in the regulation, procurement, distribution, and sales of drugs in developing countries.
Currently in its pilot stage, the Alliance hopes its activities will address several challenges in developing
countries, including the prevalence of counterfeit drugs, lack of access to affordable treatment for poor people,
and lack of quality distribution systems for medicine delivery.
2. Track and Communicate: Our research also identified a lack of emphasis on identifying, tracking, and
communicating the economic impacts of efforts that pharma companies are already engaged in. As the
examples in this paper show, a variety of different types of activities that the industry engages in for the primary
purpose of expanding access to health care – such as training, licensing, and technology transfer – often create
economic opportunities in developing countries at the same time. Yet, very few of these programs are designed
to identify, track, or communicate about economic impacts. While rigorous longitudinal economic impact
studies can be costly and time-consuming, various other methods such as small focus groups or informal
interviews with beneficiary organizations can provide pharma companies with tangible evidence of economic
opportunities created through their programs. Focusing on these very powerful positive outcomes and
undertaking simple measures to track impact provide the industry with the opportunity to highlight its
economic footprint without the need for large additional investments. Communicating about the economic
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benefits of their operations also allows the industry to supplement their messages about the value they bring
to society, beyond health care.
3. Collaborate to Maximize Impact: Finally, collaboration within and outside the industry can play a significant role
in multiplying the economic opportunity impacts of pharma companies’ activities. While not all activities lend
themselves equally to collaboration (e.g., foreign direct investment), many of the examples highlighted in
this paper feature successful partnerships. In creating economic opportunities, pharmaceutical companies
can collaborate with other industries (e.g., GSK partnering with Accenture to provide training), academic
institutions (e.g., Lilly with Purdue University for technology transfers), or even with their competitors
(e.g., the International Federation of Pharmaceutical Manufacturers and Associations developing clinical trial
and regulatory capacity or the Medicines Transparency Alliance tackling counterfeiting and distribution system
challenges). Collaborations allow partners to focus on their comparative advantages to increase impact, share
risks, and increase the credibility of the efforts with other important stakeholders.
The activities highlighted in this paper offer powerful examples of pharmaceutical companies’ contributions
to creating economic opportunity in developing countries. However, weak infrastructure in many of these
countries – including insufficient supplies of electricity and clean water, and unreliable transportation and
distribution systems – often limits the potential impact of these activities. These services, which foster
economic growth and a healthy society in developing countries, are also critical to companies’ ability to
establish and grow their markets. However, because the need in each of these areas is so great, effective
solutions require a greater variety and scale of resources than any one pharmaceutical company can offer.
Collaboration among different industries, as well as with governments and civil society groups, may be a
particularly effective tool for addressing some of these larger, systemic challenges.
As pharmaceutical companies become more involved in both business and philanthropic activities in
developing countries, it will be important for each company to identify the best strategies to create new
economic opportunities and to leverage the benefits of activities already underway. While the primary focus of
the industry is, and will most likely continue to be, on increasing access to health care, the potential for
expanding economic opportunities through its activities should not be overlooked as a significant outcome.
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Background Inclusive business models are the most direct strategy through which companies create economic
opportunity in developing countries. By forging strategic relationships with local suppliers and distributors or
establishing their own local presences, multinational health care companies can create possibilities for local
wealth and job creation.
An example of a successful inclusive business model is offered by Novartis’ partnership with East African
Botanicals (EAB), a wholly-owned subsidiary of the private Kenyan company Advanced Bio-Extracts. East African
Botanicals is primarily engaged in the production of artemisinin, a natural extract of the Artemisia annua plant
that is used to produce an active ingredient in Novartis’ anti-malarial, Coartem®.
Coartem® is part of a class of anti-malarial drugs called artemisinin-based combination therapies (ACTs) that are
recommended by the World Health Organization (WHO) for use in countries experiencing resistance to
conventional anti-malarial monotherapies. Currently, Coartem® is the only fixed-dose ACT pre-qualified by the
WHO for procurement by United Nations agencies. It is sold to the WHO at cost for public sector use in
developing countries.12
Novartis’ partnership with Eastern African Botanicals increased its access to artemisinin supplies and allowed it to
meet the soaring demand for Coartem® that followed the announcement of the treatment’s WHO pre-qualification
status. The partnership also resulted in the creation of thousands of better-paying jobs for local farmers and
manufacturing plant workers employed by EAB.
Motivation Novartis’ decision to partner with EAB was driven by the firm’s need to ensure an adequate supply of high-quality
artemisinin in order to meet Coartem® production targets under its WHO agreement. Historically, most Artemisia
annua was sourced from remote mountain regions in China and other parts of Asia, where the plant grows wild.
When demand for Coartem® increased dramatically in 2004,13 the yield from natural crops was insufficient to
meet Novartis’ supply needs. The company subsequently began exploring opportunities to establish partnerships
with additional artemisinin suppliers. EAB was a natural partner because its sole business objective is to produce
and distribute artemisinin. Moreover, because EAB is located in Kenya, Novartis was able to spread the risk of
crop damage due to climatic events between East Africa and South East Asia. Finally, by working directly with an
emerging company in East Africa, Novartis further demonstrated its commitment to economic improvement and
health advancement on the African continent. All of these factors combined to make EAB an especially attractive
business partner for Novartis and a key component of the company’s long-term Coartem® distribution strategy.
Activities Novartis’ partnership with EAB began in January, 2005, when EAB signed a five-year supply agreement requiring
it to vastly expand production of artemisinin. EAB’s business model relies on the cultivation of Artemisia annua
plants through both company-controlled irrigated crops and smallholder farms. Local farms and individual
farmers under contract with EAB are provided with planting material and comprehensive training in Good
Agricultural Practice (GAP) guidelines for Artemisia annua cultivation to ensure high-quality returns.14 In 2006,
EAB employed about 7,500 local farmers15 and increased production of Artemisia annua from 200 hectares to
more than 1,000 hectares.16
Cultivation of the Artemisia annua plants is the first step in the process of producing artmesinin. After the plant
leaves are harvested, they are processed in EAB facilities in Kenya and Uganda to extract artemisinin, which is
then shipped to Novartis and used to produce artemether, one of the active ingredients in Coartem®. 2007 marked
the first year of product delivery to Novartis; all 17 batches of the first shipment of artemisinin were approved.17
5.1 CREATING INCLUSIVE BUSINESS MODELS: NOVARTIS
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Impact The partnership between Novartis and EAB has created significant business and social impact for all parties
involved. On the business side, the partnership was the key driver behind EAB’s rapid growth. “Novartis has
proven to be our most important partner as we move to large-scale production of artemisinin in East Africa. By
placing firm orders for extracted artemisinin, providing financial support for infrastructure improvements, and
delivering technical support and know-how, Novartis has made a major contribution to creating a sustainable
market for this key natural ingredient,” said Patrick Henfrey, Chief Executive Officer of Advanced Bio-Extracts.18
The supply contract marked a major milestone for EAB, which until that time had struggled to find farmers
interested in growing Artemisia annua, or investors who would provide capital to sustain and grow the business.
The agreement with Novartis helped the company overcome both challenges. Philip McLellan, Managing
Director at EAB, explained that the promise of large-scale artemisinin purchases from a major pharmaceutical
company reduced the risk to farmers in switching crops.19
The company was also able to attract new investors after Novartis offered financial support and technical
assistance to help bring its operations to scale.20 The infusion of new capital enabled EAB to construct a multi-
million dollar processing plant in Kenya and purchase and expand a similar factory in Uganda, acquiring the
necessary building materials from local manufacturers.21 These improvements to EAB’s infrastructure have
helped position the company for long-term success in the artemisinin sales market.
For Novartis, the partnership enabled the company “to meet our own production goals for Coartem® and bring
this life-saving medicine to millions more patients suffering from malaria,” says Sivlio Gabriel, Executive Vice
President, Malaria Initiatives for Novartis. During 2006, Novartis supplied more than 62 million Coartem®
treatment courses to more than 30 countries across Africa. The company estimates that it has now reached
capacity to distribute about 100 million treatment courses each year, with appropriate notification.22
For thousands of residents of East Africa, EAB offers highly paid farming and manufacturing employment
opportunities that had previously been unavailable. Due to the high demand for Artemisia annua, the crop is
expected to deliver higher financial returns than coffee, and four times the return of corn.23 In 2006, 850
smallholder farmers in Northern Tanzania saw their incomes rise a total of $320,000 ($376 per farmer on
average) after selling their Artemisia annua crops to EAB.24 As more pharmaceutical companies begin
manufacturing greater quantities of ACTs, the increased demand for Artemisia annua will likely mean
more job creation in the region in addition to higher pay.
Finally, the increase in the number of Coartem® treatments made available through partnerships like the one
between Novartis and EAB has meant that more poor people in developing countries have access to the life-
saving medicines they need. The 62 million Coartem® treatments distributed by Novartis in 2006 helped
save an estimated 200,000 lives.25
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Background Inclusive business models are the first tier of activities and the most direct method that health care
companies can employ to create economic opportunity in a developing country. Inclusive business models,
which stem from value chain linkages, are at the core of a firm’s activities. Examples include foreign direct
investment (FDI), international partnerships, technology transfers, outsourcing, voluntary licensing and the
incorporation of local firms into the supply chain. Inclusive business models have the potential to increase
local sales, procurement, and employment in a developing country.
AstraZeneca has utilized this model by embarking on a significant expansion of its operations into India, most
recently culminating in the establishment of a Process Research and Development (PR&D) laboratory in
Bangalore. AstraZeneca’s inauguration of the PR&D laboratory in March, 2007, complemented its existing R&D
center and manufacturing and marketing offices in India. The new PR&D laboratory, only the fourth built by the
company, is AstraZeneca’s first such facility outside of Europe.
Motivations AstraZeneca’s expansion into India is motivated by strategic business opportunity. Approximately 30% of
tuberculosis (TB) cases in the world occur in India and the new PR&D facility, in conjunction with the existing
R&D center, is focused on finding a cure for TB. Moreover, according to Dr. Tanjore Balganesh, head of
research at the Bangalore AstraZeneca unit, currently available TB drugs, while effective against the disease,
possess many side effects, have prolonged treatment periods, and are highly toxic. By leveraging India’s
strength in process chemistry, AstraZeneca expects to develop a new drug to combat TB by 2012.26
In addition to the core strategic business motivation, AstraZeneca has been motivated by its corporate social
responsibility efforts to combat TB in other high-incidence areas in Central Asia, namely Kyrgyzstan and
Turkmenistan. Partnering with the Red Cross in 2002, AstraZeneca’s Bangalore division funded community-
based programs. These programs built local capabilities in prevention and control of the disease, and
improved education awareness about TB and the advantages of early diagnosis. As a result of the progress
from these programs – increased number of diagnosed patients, higher treatment completion rates, and a
greater sense of general awareness – AstraZeneca’s R&D center received the 2005 Corporate Community
Partner Award at the Pharmaceutical Achievement Awards Conference.27
Activity The new PR&D facility cost $15 million to build. It can accommodate up to 80 process scientists, supported by
Description a contingent of engineering and office staff. While AstraZeneca will hire scientists from leading research
facilities around the world, many of the employees who operate the Bangalore facility will be from India.
Together with the existing R&D center, the new PR&D facility is an earnest attempt to address a neglected
disease common to India and the rest of the developing world. Currently, AstraZeneca is the only major drug
company to have established an R&D center and PR&D facility to develop new drugs in India.28
Impact As with many pharmaceutical-related investments, the financial benefit of the new project is expected to occur
– over an extended period of time – once the drug has been created, approved, and released onto the market.
Meanwhile, AstraZeneca has made significant investments in creating social impact through the project.
To date, AstraZeneca has invested over $50 million in its Bangalore-based facilities, including $15 million to
build the PR&D laboratory and $40 million in the R&D center for construction, equipment, and research
programs on drug discovery. The total employment created through AstraZeneca’s India operations is anticipated
to exceed 400 in 2008. This number includes 300 manufacturing staff from an existing drug formulation plant,
90 scientists from the R&D center, and 80 scientists who will fill the new PR&D center by mid-2008. This
estimate does not include staff and engineers for the new PR&D facility.29
5.2 CREATING INCLUSIVE BUSINESS MODELS: ASTRAZENECA’S EXPANSION IN INDIA 5.1
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AstraZeneca’s inclusive business model approach in India has created jobs across a range of skill levels – from
highly-skilled scientists and engineers to auxiliary and support staff. Moreover, AstraZeneca continues to create
greater economic opportunity through related and supporting industries. These opportunities are the product of
value chain linkages in the form of distributing, supplying, outsourcing, and collaborating agreements with local
firms. For example, AstraZeneca has outsourced some of its scientific work to third-party Indian firms.
AstraZeneca’s inclusive business model in Bangalore has created a “strategic cornerstone” that serves as a
platform for complementary strategies that magnify its economic opportunity impact. For example, beyond the
company’s core activities, AstraZeneca has supported education and training opportunities through organized
seminars, symposia, and workshops.
Sudhir Nambiar, the director of the PR&D facility, commented, “Depending on the Bangalore team’s performance
during the coming year, the center may get a pilot plant with enough capacity to support human trials.”30
AstraZeneca’s continued expansion may increase incentives for other pharmaceutical companies to open or
expand operations in India. This would create a multiplier effect in which all parties involved, into the lower-
income strata, benefit.
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Background Voluntary licenses form part of the inclusive business model strategy through which pharmaceutical companies
can create economic opportunities. Voluntary licenses (VLs) are formal permissions granted by patent holders of
branded drugs through which manufacturers in developing countries can produce and sell generic versions. Since
generics are often cheaper than their branded counterparts, or have wider distribution, VLs create better access
to drugs. By allowing generics manufacturers the legal right to produce drugs they would otherwise lack access
to, VLs can foster local business development, job creation, and improved public health.
GlaxoSmithKline (GSK) has been a leader in the field of voluntary licensing, having granted eight VLs to date to
generics manufacturers in South Africa and Kenya. “I think we’ve granted more voluntary licenses than most
other players in the industry,” says Jon Pender, Director of Government Affairs at GSK. “We have taken a very
progressive attitude in dealing with this challenge.” All of GSK’s licenses have been for anti-retroviral (ARV) drugs
used to treat HIV/AIDS.
Motivations A combination of business and philanthropic needs drove GSK’s decision to initiate voluntary licensing of
its ARV drugs. First, according to Pender, the company simply recognized that licensing was the right
thing to do, given AIDS’ massive toll in the developing world. Second, providing tangible solutions to the AIDS
pandemic helped improve the company’s reputation and its relationships with strategic stakeholders at a time
when the pharma industry was under significant pressure to act. Finally, the agreement helped preserve the
company’s business model, which relies heavily on a strong intellectual property rights regime. “People did not
fully understand our constraints, and we needed to protect the fundamental business model. Providing the
licenses allowed us to address the global health challenge and protect our intellectual property without
compromising patent rules,” explains Pender.
The recipient companies also reaped numerous benefits from the agreement. GSK’s products were commercially
attractive to the licensees, since they could access rights to produce first-line ARVs, and generate revenues
leading to increased profits. For companies like Aspen Pharmacare, establishing a relationship with a major
multinational pharma company paved the way for additional partnerships with other companies. The agreements
also allowed the local generics companies to contribute to the local economy, address a critical public health
challenge in their countries, and highlight their own social responsibility.
Activities GSK has issued eight voluntary licenses to date, starting with Aspen Pharmacare in South Africa in 2001.
The other companies are Cosmos in Kenya (2004), Biotech Laboratories (2004), Feza Pharmaceuticals (2004),
Cipla Medpro (2004), Universal Coporation Limited (2005), Adcock Ingram (2005), and Ranbaxy (2006), all in
South Africa. GSK’s licencees are all producing their own versions of GSK’s ARVs rather than manufacturing on
GSK’s behalf. Consequently, GSK’s key responsibility is to ensure that the generics manufacturers are capable of
producing to global quality standards. To ensure this, GSK undertakes a rigorous due diligence process before
selecting each licensee. Each recipient company is selected on the basis of its technical capabilities, and any
technology transfer for the manufacturing process is built into the licensing partnership. The responsibility to
ensure that the products are of good quality lies with the licencee and with the local regulatory authorities. As a
result, once the agreement is in place, there is not a significant need for skills transfer or technical assistance.
Licensees usually buy the necessary active pharmaceutical ingredients for the drugs from India or China, then
produce the treatments and work with local regulatory agencies to obtain approval before selling to local markets.
While GSK is open to discussing VLs with other partners, it is also realistic about the challenges and benefits
of these arrangements. The company considers it vital to choose the most appropriate licensees – those who
can ensure the sustainability of supply, encourage safe use of the drugs, and ensure the medicines go to the
patients who need them, rather than being diverted to wealthier markets.31
5.3 CREATING INCLUSIVE BUSINESS MODELS: GSK’S VOLUNTARY LICENSES
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Impact The VL’s impact has already been seen in terms of building local ARV manufacturing capability. In 2005, GSK
shipped 126 million ARV tablets. In 2006, the company shipped just 86 million tablets, yet total shipments
increased to 206 million, as shipments from the locally-licensed manufacturers provided the balance of 120
million tablets.32
GSK has also benefited through improved stakeholder relations. “We have seen a lot of interest from informed
stakeholders, such as Oxfam, the investor community, and political leaders,” says Jon Pender. “While it’s difficult
to say exactly how much public opinion has changed due to the VLs specifically, it’s the overall package of our
activities in this area that has made a difference in our reputation.”
Since GSK is not directly responsible for the generic manufacturing process once a license has been issued,
the company does not currently track the impact on licensees beyond their production volumes. However,
conversations with Aspen Pharmacare identified several tangible benefits for the generics manufacturer.
“We are probably the single biggest generic supplier to sub-Saharan Africa,” says Stavros Nicolaou, senior
executive at Aspen. “Today ARVs contribute about 7–8% of our total revenue, up from 0% before the
agreements.” In addition, the licensing agreement has allowed Aspen to apply lessons learned from its initial
experience with GSK to more sophisticated partnerships it later established involving technology transfers for
drugs in additional therapeutic areas (see Lilly case study for more detail). “We’ve gone from rudimentary
licensing agreements and immunity of suits to more advanced technology transfer partnerships, and have learned
along the way, as no two technology transfer agreements are the same,” comments Nicolaou.
In addition to direct impact on licensee companies, the VLs also have multiplier effects in other markets that are
connected to those companies. Since many of these African manufacturers import their raw materials from
companies in India and China, the economic impact of the VLs extends to those companies and countries as well.
The Role of One of the key lessons GSK learned through the licensing process was that partnerships with generics
Collaboration manufacturers involve multiple steps and almost always take longer than originally planned. Hence, proper
planning, well-developed timelines and milestones, and realistic expectations from the beginning are all
important. Pender also notes that personal relationships are critical in establishing business partnerships.
“The individuals who are involved on both sides can make a big difference in the partnership,” explains Pender.
“You need to enter into dialogues with many different kinds of stakeholders and need to build trust in that
process. The personal relationships and trust allows you to weather the challenges in the process.”
Aspen’s experience working with GSK has helped it identify best practices for other local manufacturers
seeking to establish similar partnerships going forward. Aspen’s relationship with GSK has not only helped
position the company as a partner of choice for other Western pharma companies, but has also helped build
its internal capabilities and its reputation with the United States Food and Drug Administration. Says Nicolaou
of Aspen, “We’ve learnt a lot through experience, since sometimes you only find the errors six months down
the line. We’re a lot smarter now. We’re in a better position to gain experience from future partnerships and
technology transfers.”
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Background Technology transfers are another example of an inclusive business model strategy through which pharmaceutical
companies can create economic opportunities. Technology transfers by Western pharmaceutical companies to
developing country drug manufacturers play an important role in creating new jobs and expanding business
opportunities for local drug manufacturers. Eli Lilly’s effort to address multi-drug-resistant tuberculosis (MDR-TB) by
transferring the manufacturing technology of their two TB drugs – cycloserine (Seromycin®) and capreomycin
(Capastat®) – is a prominent example in this category. MDR-TB is a drug-resistant strain of TB that has emerged over
the last several years as a result of poor adherence to TB treatment by patients in developing countries. The WHO
estimates that more than 400,000 new cases of MDR-TB are diagnosed each year.33
Started in 2003, the Lilly MDR-TB Partnership is a unique public-private health initiative with the goal of controlling and
ultimately eliminating multi-drug-resistant tuberculosis. As part of this philanthropic initiative, Lilly has made the
manufacturing technology for its two MDR-TB drugs, capreomycin and cycloserine, available to pharmaceutical
companies in some of the countries with the highest MDR-TB burdens: China, India, Russia, and South Africa. As a key
component of this technology transfer, Lilly partners with Purdue University to provide training and expertise to locally-
based pharmaceutical companies to help ensure that high-quality manufacturing processes are in place and that the
companies are well positioned for long-term sustainability.
Motivation The MDR-TB partnership and the resulting technology transfer agreements are philanthropic activities undertaken by
Lilly to tackle the threat of the deadly disease. “We have no in-house infectious disease drug discovery group, so this is
truly a philanthropic effort,” explains Dr. Gail Cassell, Vice President for Scientific Affairs and Distinguished Research
Scholar for Infectious Diseases at Lilly. Although the partnership is a philanthropic activity, it is unique in that it
capitalizes on Lilly’s core competency as a drug manufacturer to transfer technical capabilities to the developing world.
While creating economic opportunity for the manufacturing partners was not the primary goal of the MDR-TB initiative,
it is an important outcome of the technology transfers: “Our direct intent initially was not for the promotion of economic
opportunity or development in the countries, but certainly it is a positive outcome of our activities,” adds Cassell.
In addition to taking advantage of the company’s R&D resources, the partnership also delivers business value to Lilly.
Transferring its production capacity to Aspen allows Lilly to devote its research and development resources
to products that support its core business strategy. As a 2004 case study by the African Institute of Corporate Citizenship
observed, “Through this initiative, Eli Lilly demonstrates how a company’s investment can be managed to actualise the
benefits to society in a situation where the entity has other overriding interests preventing it from following through with
the investment/product on its own.”34
Activities Lilly has established technology transfer agreements with companies in the four countries with the highest MDR-TB
burdens – South Africa (Aspen Pharmacare), China (Hisun Pharmaceutical), India (Shasun Chemicals and Drugs), and
Russia (SIA International) – as well as a partnership with Purdue University in the United States. In addition to supplying
the necessary manufacturing technology and expertise to produce cycloserine and capreomycin, Lilly provides financial
assistance for the purchase of equipment and conversion of manufacturing facilities, and technical training for the
different steps in the manufacturing process. Lilly’s partnership with Purdue University brings foreign scientists and
plant managers from recipient companies to the university for training in manufacturing skills and good business
practices. This partnership provides a powerful example of how multinational companies partnering with institutions in
their own countries can also help create economic opportunities in other countries.
Impact Lilly’s technology transfer activities are creating positive financial and operational impacts at all of the beneficiary
companies. In South Africa, Aspen Pharmacare manufactures both cycloserine and capreomycin. Aspen sold its first
batch of cycloserine to Botswana in 2005, and is currently preparing to open a new facility with a capacity of 4 billion
capsules per year. In 2006, the company also began construction of a plant to produce capreomycin, funded in part
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by Lilly. As a result, South Africa’s profile as a manufacturing and pharmaceutical base is expected to be boosted.
Enhancing Aspen’s manufacturing capacity has generated new jobs and may also enhance South Africa’s balance of
payments through additional revenues from exports.
The partnership with Lilly has enabled Aspen to provide a skilled labor base and develop new skills for the local labor
pool. Noting that the pharmaceutical industry is highly automated, Stavros Nicolaou, Senior Executive at Aspen,
comments that these initiatives have led to some job creation in South Africa, a country saddled with a high
unemployment rate. “From a human resource point the most impressive aspect of these arrangements has been the
ability to retain and grow new skills, all of which contribute to the expanding of the South African economy and in
particular in stemming the tide against the devastating pandemics of HIV, AIDS and TB.” Aspen’s relationships with
Western companies such as Lilly and GSK helped the company secure approval as a United States Food & Drug
Administration drug manufacturer. Due to the technology transfer, the company is now able to produce drugs from
molecules which they did not have access to earlier. “These types of partnership have given us increased volume in
our factories – without that, you can’t be competitive,” explains Nicolaou.
The Chinese manufacturer Hisun Pharmaceutical produced its first batch of the capreomycin active ingredient in May
2006. Hisun is also building a second facility to produce vials of the capreomycin final drug in early 2009. Shasun
Chemicals and Drugs in India has validated its manufacturing process for cycloserine, and dispatched its first order to
Aspen in February 2006. Finally, the Russian manufacturer, SIA International, is Lilly’s newest drug-manufacturing
partner and is one of Russia’s largest pharmaceutical companies. SIA will supply both Lilly MDR-TB drugs.
The transfers may also have multiplier effects on the developing world manufacturers, allowing them to expand to
other products beyond MDR-TB utilizing the resources from the partnerships. “We would make the case that now that
we’ve transferred the technology to them, and we have enhanced their capabilities through training, they now have
other opportunities to produce other products that will be in compliance with Good Manufacturing Practices [GMP],”
says Cassell.
Lilly recently announced a new not-for-profit early-stage drug discovery effort for TB, which Cassell hopes will enable the
company to engage scientists and pharmaceutical companies in low-income countries, particularly those countries with
high disease rates. “This could improve their capabilities and provide economic opportunities for them individually, and
possibly lead to collaborations with companies in their countries,” she notes.
The Role of An important lesson from Lilly’s technology transfer activities is that it is possible for pharmaceutical
Collaboration companies to enter into complementary agreements with generic manufacturers that lead to better economic and
health impacts for developing countries. The Lilly MDR-TB Partnership represents a true win-win scenario. For Aspen, it
provides an opportunity to expand the company’s market share in South Africa and other African markets. For South
Africans, the activities provide opportunities for new jobs, increased incomes, and better protection from a deadly
disease. And Lilly is able to concentrate its research efforts on its core business areas, while gaining reputational
benefits as a good corporate citizen.
Comments Cassell, “We feel it has been a very important and impactful philanthropic effort, and clearly it has increased
access to treatment for this unbelievably complex disease. We are glad that we made the decision
to invest in this area. We would encourage other pharmaceutical companies to use this model – transferring
manufacturing know-how to developing countries. It increases access to medicines and also increases technical
capabilities in these countries so there are opportunities for economic development.”
Lilly’s partnership with Purdue has had an impact not only on the generics manufacturers but also on the university itself.
The partnership has been able to leverage other resources to achieve this additional impact. For example, a Purdue
alumnus donated funding to establish a GMP center on campus. The center provides training for Lilly’s manufacturing
partners in GMP, but is also available to Purdue’s students, allowing them to gain an appreciation for the need to involve
both public and private sectors in these efforts. Says Cassell, “There’s a lot of merit in partnering with universities who
have manufacturing abilities and are interested in solving problems related to medicine access in developing countries.”
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Background Human capacity-building initiatives are part of the second tier of activities through which companies enhance
economic opportunity in developing countries. Multinationals and other large companies can participate in building
human capacity by supporting vocational training or professional development programs, technical support,
networking assistance, or mentoring time. Initiatives that target human capacity-building for health care workers are
strategic philanthropic investments because pharmaceutical companies rely on highly skilled care providers for the
adoption and uptake of their products.
The case studies below provide detail on the human capacity-building programs operated through the philanthropic
arms of several multinational pharmaceutical companies, including Abbott, GlaxoSmithKline, Pfizer, and Novo Nordisk.
Abbott and Abbott and Abbot Fund’s program to strengthen health care systems in Tanzania is a comprehensive
Abbott Fund philanthropic initiative aimed at meeting the needs of people with HIV/AIDS and other lifelong diseases. Launched in
2001 as a public-private partnership with the Government of Tanzania, the initiative has helped to modernize
facilities, train staff, improve hospital and patient management, and expand capacity for HIV/AIDS testing and
treatment at over 90 hospitals and rural health clinics across the country. To date, Abbott Fund has invested more
than $50 million in the initiative, in addition to providing the technical expertise of Abbott employee volunteers to
address a range of critical health areas.
A central component of the Tanzania initiative is its focus on developing human capacity: to date, over 10,000
professional and community-based health care workers have been trained in HIV care and treatment, voluntary HIV
counseling and testing, laboratory equipment operation, hospital information technology, and hospital management.
The training programs have had a significant impact on local health care infrastructure. Staff working at facilities
funded through Abbott’s initiative operate one of the most extensive hospital IT systems in East Africa to track
health history, referrals, test results, and drug prescriptions. At Muhimbili Hospital, the national teaching hospital, a
strong management team has increased hospital revenues by more than 50% in the first two years since the
program began. Access to care has also improved as a result of the training program. About one in three people
enrolled in the government’s national HIV treatment program receive services at a facility that has benefited from
Abbott Fund improvements.
Evidence of increased economic opportunity for program participants is more difficult to document. As Reeta Roy,
Vice President of Abbott Fund and Divisional Vice President, Global Citizenship and Policy at Abbott explains, “Our
program metrics align with our objectives to improve health care services.” Roy emphasizes that while Abbott’s main
goal in designing its initiatives is to expand access to quality health care, program investments have helped create
an enabling environment for the poor to manage their assets. “We have observed that investments in health care
enhance livelihood options for low-income families. However, quantifying this impact is challenging.”
Abbott and Abbott Fund’s work in Afghanistan is another example of a high-impact human capacity-building
program. The goal of this program is to improve maternal and infant health in a country that has the second-highest
maternal and infant mortality rate in the world. The program also has an explicit emphasis on increasing economic
opportunity for program participants.
Through its partnership with Direct Relief International and the Afghan Institute of Learning (AIL), Abbott Fund has
provided more than $230,000 in grants to support two nine-month intensive nurse/midwife/health educator
workshops in Herat and Kabul. All 19 women from the program’s first graduating class are utilizing the skills they
obtained, with 11 graduates working at local hospitals and health centers. 16 additional women completed desk
and/or clinic training and are qualified as health educators and science teachers. The success of the program created
significant demand for health training among the women in the community, resulting in twice as many applicants as
spaces available for the next training session. The program also revealed tremendous need for general health
education by women in the community. Based on these findings, |a new program was initiated this year by AIL, and
Abbott provided a grant to support 15 community health workshops in Herat and Kabul provinces. Four of the 15 have
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already been completed. Additionally, a third party recently approached AIL and Abbott in hopes of replicating the
workshops in the surrounding areas of Bamiyan.
Abbott also donated $3.2 million in products (including nutritionals, vitamins, and antibiotics) for distribution at three
clinics associated with the program. This comprehensive support has more than doubled the capacity of these clinics to
serve women and children, and has enabled the clinics to reallocate funds used for purchasing products to delivering
services. Within the first year of the program, the three clinics saw a significant increase in their capacity to serve
patients. Compared to baseline, the clinics treated 56% more patients, increased reproductive health services by 17%,
and vaccinated more than three times as many patients as before the program began.
The Abbott Fund programs have had multiplier effects in developing countries. By strengthening public health systems and
improving individual health, the programs have fostered an environment that enables individual and community economic
development. “The private sector and foundations have an important role as change agents in international development,”
Roy explains. “While the lives that we touch gain from programs we support and from our expertise, our companies benefit
by learning how to operate in new and challenging environments.”
GlaxoSmithKline Similar to Abbott’s Afghanistan program, GlaxoSmithKline (GSK) sponsors several initiatives aimed at training nurses,
midwives, and other health care workers to provide primary and maternal care for people in developing countries.
GSK’s Thai Nursing program was the longest-running of several initiatives throughout southeast Asia, having trained
500 nurses over a five-year period in subjects including primary care, health care prevention and promotion, patient
home visitation, disease management and control, and health promotion campaigns.
The Thai program’s goal of increasing economic opportunity for women is particularly important in the context of the
Thai economy, notes GSK’s Vice President of Global Community Partnerships, Justine Frain. “In Thailand, the nursing
training program provides a much-needed opportunity for underprivileged young women who might otherwise have
turned to prostitution. Our program enables them to develop skills that will allow them to go back to villages in rural
areas and carry on working there and use their skills to work as nurses.”
Graduates from the Thai nursing program are now working in 85 community hospitals and 24 public health centers in
40 provinces across Thailand. While corporate funding for the program is now complete, the Thai Royal Family was so
impressed by the results that it partnered with the local GSK office to continue offering the training courses.
GSK has funded a similar program in Viet Nam aimed at improving access to care for women from ethnic minority
groups. Students in that program train for six months in subjects including prenatal care, midwifery, infectious disease
prevention, and social work. Upon graduation, they return to work in isolated rural villages, where they report to
provincial health services.
A critical success factor in both programs, according to Frain, is GSK’s commitment to working with locally-based non-
profit partners to execute the training programs. “Our principle is to try to identify an organization that can provide
services and deliver the program in a particular location, because what you would deliver in Thailand is different from
what you’d do in Indonesia.” Additionally, where GSK has local company offices, staff in those offices are also involved
in the program design and implementation. “It’s very arrogant to go in and think we can do something on their turf
without their insight and involvement.”
Pfizer Pfizer’s sponsorship of the non-profit Infectious Diseases Institute (IDI) in Uganda offers another example of a capacity-
building initiative that indirectly enhances economic opportunity for people in developing countries. Originally
constructed with financial and technical support from Pfizer, IDI’s mission is to build capacity in Africa for the delivery
of sustainable, high-quality care and prevention of HIV/AIDS and related infectious diseases through training and
research. The Institute is a major center for training African medical professionals in advanced HIV/AIDS management
techniques. Training programs offered through IDI include:
• an intensive, three-week HIV/AIDS course for physicians which includes lectures, bedside and clinical teaching,
clinical case discussions, journal clubs, and group project work;
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• one- and two-week multi-disciplinary courses targeting nurses, midwives, clinical officers, counselors and
laboratory technicians; and
• modular courses on more specific topics offering health care workers from different backgrounds and workplaces
the opportunity to develop skills based on the needs of their home institutions.
Since 2004, the state-of-the-art facility has trained more than 1,400 health care providers from 26 African countries.
Although data regarding the placement of training program graduates is unavailable, a 2005 survey showed that 98%
of IDI alumni were providing anti-retroviral therapy and other forms of care for people living with HIV/AIDS. Perhaps
even more significantly, 100% of survey respondents said they had trained other health workers in HIV care, with each
alumnus sharing their new skills with about 20 health workers per month. As one IDI graduate put it:
“We have been running an opportunistic infections clinic but we discovered that we didn’t have enough doctors and
nurses who were capable of managing HIV. I contacted the Government, which agreed to send me for this training.
The information I have got within this short period of time is more than enough. I have learnt a lot about
management of opportunistic infections and ARVs. There was also a train-the-trainer aspect, so I will be able to go
and train others. Since we don’t have enough doctors and nurses who are capable of managing ARVs, definitely I will
be a resourceful person.”35
Novo Nordisk Novo Nordisk established the World Partner Project (WPP) in 2001 in response to the WHO’s four recommendations
for dealing with chronic diseases. The purpose of the initiative is four-fold:
• to improve the outcomes of diabetes therapy;
• to fulfill Novo Nordisk’s social responsibility;
• to address the ongoing public debate criticizing the pharmaceutical industry; and
• to find models for improving the global treatment of diabetes in the world’s developing countries to benefit both
patients and the company.
The WPP initiative is currently active in eight countries: Bangladesh, Malaysia, Tanzania, Zambia, El Salvador, Costa
Rica, China, and India. This case study focuses on WPP’s presence in Bangladesh.
The WPP’s main partner in Bangladesh is the Diabetes Association of Bangladesh (DAB), which is the main provider of
diabetes care in the country, with a network of hospitals and clinics serving about a third of the diabetes population.
One of WPP’s key activities in Bangladesh is a distance-learning program originally developed for doctors working in
DAB clinics and later expanded to doctors at most public and some private clinics in rural areas. Many of these
physicians did not have access to continuing medical education opportunities given their remote locations. Over the
past five years, the WPP program has provided training in diabetes prevention and care to more than 400 doctors. A
similar program was developed for nurses, utilizing a train-the-trainer approach that has created a ripple effect on
nurse training in the country. To date, more than 100 nurses have participated in the program.
These programs have improved the skill sets of hundreds of medical professionals in Bangladesh and have also had a
significant impact on the general awareness level regarding diabetes prevention and care in the country. Peter
Gerhardsson, Vice President of Corporate Responsibility for Novo Nordisk, explains, “The success here has been that
we’ve really gotten many of these countries to realize that they have another chronic disease problem that will hit
them harder ten years from now. There’s a success in awareness-building.” This educational outcome also has
implications for Novo Nordisk’s future business interests in developing countries. “We’re always looking at the
business opportunity. In some countries, we may not currently have a large market presence, but the need for
infrastructure is there. The business opportunity will come later.”
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Background Institutional capacity-building efforts form part of the second tier of activities through which health care companies
create economic opportunity. Types of activities in this tier include technical support, financial support, networking
assistance, strategic planning advice, and in-kind resources. The International Federation of Pharmaceutical
Manufacturers and Associations (IFPMA) is developing a collaborative, industry-based approach to building health
care management and infrastructure capacity in developing countries through education and training programs. This
effort provides an excellent example of an institutional capacity-building initiative with high potential for both social
and business impacts.
The IFPMA is a non-governmental organization that represents national industry associations and companies in the
pharmaceutical, biotech, and vaccine industries. One of IFPMA’s main objectives is to contribute industry expertise
and foster collaborative relationships and partnerships with international organizations, national institutions,
governments, and non-governmental organizations that are dedicated to the improvement of public health, especially
in developing and emerging markets.36 To that end, the organization recently created a working group, called the
Partnership Taskforce, that will develop collaborative initiatives aimed at addressing bottlenecks in the drug
development, manufacturing, and distribution systems in developing countries. The three main areas of engagement
include:
• building institutional capacity;
• improving supply chain management; and
• establishing an industry network for research and development for neglected diseases.
This case study focuses on industry efforts related to institutional capacity-building, which has a direct impact on
economic opportunity in developing countries.
Motivations The basic business imperative to maintain cost-effective and efficient operations provides a main motivation for
engagement in institutional capacity-building initiatives in developing countries. Companies’ ability to develop,
produce, and distribute high-quality medicines in a timely manner is heavily dependent upon the existence of a
robust and well-managed health care infrastructure, which does not exist in many developing countries. In those
countries, limited local capacity for directing clinical trials, registering and regulating drugs, and conducting quality
assurance activities has restricted companies’ ability to operate effectively. In some countries, the delay in bringing
new drugs to market can be years, and products often reach stores with limited shelf life remaining. In addition, says
Stefanie Meredith, Director of Public Health Partnerships for IFPMA, “If industry is going to develop new products for
diseases in the developing world, it needs to be able to do the clinical trials appropriately, efficiently, and ethically.
Most countries have limited experience with this, so this is an area that needs to be better organized and built up.”
Significant improvements in the areas of health care management and government capacity are necessary in order
to address these challenges and improve the business environment for pharmaceutical and other health care
companies.
The social consequence of limited access to medicine for people living with treatable diseases provides an equally
compelling case for engagement in institutional capacity-building initiatives. Notes Meredith, “The top priority here is
meeting an unmet medical need. Some of these efforts are things that only industry can offer – their core
competencies around training, supply chain management, etc. They should be able to have a significant social
impact in addition to the economic benefit.”
The IFPMA taskforce on institutional capacity-building offers a powerful example of an initiative that leverages
companies’ core competencies to create both business and social impacts in developing countries. Ultimately,
increased local capacity will result in a better business environment for companies, increased economic
opportunities for local residents, and expanded access to medicines and related health care services for citizens of
the affected countries.
5.6 INSTITUTIONAL CAPACITY-BUILDING: INTERNATIONAL FEDERATION OF PHARMACEUTICAL
MANUFACTURERS AND ASSOCIATIONS
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Activities The IFPMA created the Director of Public Health Partnerships position in the fall of 2006 to help member
companies think and act more strategically around public health issues. What had been missing in companies’
strategies to date was not action, notes Meredith, but rather coordination and collaboration. “What we’ve been
talking about since [the taskforce was launched in] March is, what can we do collaboratively that uses core
competence and will have an impact. Every company has done something good and useful, but the initiatives are
all bilateral. To have an impact on public health, we have to look at what can be done in a collaborative fashion.”
Meredith began by establishing a taskforce comprised of industry players who were interested in exploring ways of
engaging more strategically and collaboratively in developing countries. “We started off with several key questions:
what are the needs in these countries, where are the gaps, what are you willing to do and what can we contribute?”
explains Meredith. The taskforce members identified several areas of need where the industry was well-suited to
make an impact through collaborative action. Those areas – capacity-building, supply chain management, and drug
discovery – are now the focus for the Partnership Taskforce, and industry participants have been identified to lead
each effort.
The capacity-building subgroup identified three areas of need on which its efforts will focus: clinical trial capacity,
drug registration and regulation capacity, and quality assurance capacity. Each of these processes is a key step in
the path from drug discovery to drug distribution; efforts to increase local skill and competence in each process will
directly improve companies’ ability to bring drugs to market in a timely and efficient manner.
The subgroup identified the scarcity of professional education and training opportunities for government health
agency employees as the major impediment to increased institutional capacity. The subgroup is now exploring a
range of opportunities to engage in training clinicians, scientists, and other workers. Training in clinical trials and
quality assurance, for example, could be developed by the companies and offered in their labs, and mentors could
be made available to support trained staff in their home countries.
A specific challenge facing the capacity-building subgroup relates to industry engagement in training drug
registration and regulation workers. As Meredith notes, “Industry knows where the regulatory problems are, but we
can’t train regulators. We can help find the funding to pay for the training, though. We can spend some time at the
WHO where they are looking at their own programs.” This collaborative approach to institutional capacity-building
allows member companies to achieve their desired impact without creating a conflict of interest.
The work of the capacity-building subgroup is designed to bolster local and national health care management and
infrastructure through expanding training opportunities for local scientists, clinicians, and government workers. “We
believe that countries deserve the best possible training to manage these functions themselves in partnership with
the industry companies,” says Meredith.
Impact The IFPMA taskforce is still in its earliest stages of information gathering and program design; however, it has already
gained momentum among industry members. Recognizing that conversations about industry engagement in
developing countries are often challenging and fraught with concerns over company image, Meredith was careful to
establish a good working environment to encourage participation among industry partners. “The second meeting
brought in more people than the first, and since then there’s been even more interest. People in different companies
have heard that the meetings were successful and that they provide a good environment.” Securing buy-in from
additional companies will allow taskforce programs to reach greater scale, leading to increased impact on the ground.
Taskforce members have begun to research other models of institutional capacity-building (e.g., the European
Clinical Trials Development Program), and plan to implement a few pilot training programs in the near term.
Measuring the impact of these pilot programs and other initiatives that will follow them, however, is likely to prove
difficult, according to Meredith. “If you are donating a drug, you can look at how many people are treated, but as we
get further along than drug donations, it’s a slow process to measure impact. If you’re building capacity, that takes
longer than three to five years. You can measure something from perceptions and communications, but it’s a proxy
and not particularly useful.”
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The Role of An important lesson IFPMA learned early on in the initiative relates to the importance of incorporating cultural
Collaboration awareness into the work of a global partnership. “I did the same presentation to several companies in Europe and
the United States, and their reactions were totally different. What I’ve learned is that we need to understand each
other better. We need to learn about each other’s different processes, legal restrictions, intellectual property rules,
etc.,” says Meredith. Gaining a better understanding of each partner’s operating environment and its related
competitive advantages and limitations is essential to the taskforce’s ability to leverage each partner’s core strengths
to improve the overall effectiveness of the group.
A best practice in developing institutional capacity-building programs is to ensure that new efforts complement
rather than duplicate any existing initiatives, and that new partners work collaboratively with agencies and
organizations that are already active in specific fields. “We have to bear in mind that there are other initiatives going
on around clinical trial capacity-building. We must look at how to work with other major partners – WHO and the UN
Special Programme for Research and Training in Tropical Diseases (TDR) are clearly big players. They can help in
endemic countries. We need to work with other programs that are addressing this issue, and look at what they’re
doing and complement and expand what’s already happening.”
35
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Background Rule-shaping constitutes the third tier of activities through which health care companies can create economic
opportunity. The types of activity in this tier include helping to optimize policy and regulatory frameworks related to the
business environment in developing countries, for example in the areas of tax, intellectual property, and innovation.
Merck’s Competitiveness Initiative for Latin America is one such example.
Launched in 2004 in collaboration with the United States Council on Competitiveness, the initiative aims to promote
competitiveness in the region, with initial emphasis on projects that support the development of the life science
sectors in Mexico and Brazil. Merck (known as Merck Sharp & Dohme, or MSD, outside the US) has had a presence in
Latin America and the Caribbean since 1915, and operates in nearly all of the region’s 35 countries. MSD activities
span from clinical research, manufacturing, sales, and marketing to supporting policies that promote innovation. MSD
employs several thousand people throughout the region.
Motivations Strategic business motivations led Merck to set up this ambitious program. In the long term, a healthier and more
prosperous Latin America provides greater opportunity for Merck by creating more disposable income, leading to
increased expenditure on health care. In addition, Merck’s involvement in specific partnerships through the
Competitiveness Initiative allows the company to position itself as a partner of choice for future collaborations with
local governments, businesses, and civil society. “We see ourselves as long-term investors and corporate citizens in
these markets, which necessitates investing in sustainable health care solutions, economic development, and
advocating for a policy and scientific environment that better fosters innovation,” says David Greeley, who, until
recently, headed up Merck's public affairs and policy efforts for Latin America.
Social impact is also an important motivation for Merck. “We were in part influenced by some of the work of
Jeffrey Sachs and the World Health Organization's Report on Macroeconomics and Health. Our long-term vision is
formed on the basis that health is a driver of economic development rather than an output of it,” explains Clemens
Caicedo, Senior Director of Latin America Policy at Merck. The conditions that foster business innovation, such as
the protection of intellectual property rights, are beneficial to local scientists and businesses as well as for
research-based multinational companies such as Merck. Overall, says Caicedo, "We see this competitiveness
initiative as being perceived in the national interest of countries in which we are investing, thereby creating a
constructive win-win relationship with countries south of our border.”
At a time when Western pharmaceutical companies have come under scrutiny in developing countries, the initiative
provides a powerful example of how pharma can have positive impact on local businesses, and ultimately, the
citizens of these countries. The initiative is a unique opportunity to build brand equity for Merck in Latin America
leading to future commercial success.
At the same time, though, Greeley notes that an initiative like this needs to be positioned properly within the company
to garner internal buy-in. “Because some of these activities are designed to produce long-term impact, and we are
often looking for immediate results and facing quarter-by-quarter pressures, demonstrating return on investment can
sometimes be challenging. It has to be framed in a way internally so that we get widespread support.”
Activity Over the last four years, Merck has invested about $1 million a year in the initiative. The company has taken a long-
Description term, business approach to this initiative, as demonstrated by its placement within the International Policy and Latin
America business units.
While the company’s effort to encourage innovation in the life sciences will eventually encompass much of Latin
America, the initiative initially focused on Mexico and Brazil. Merck sees these countries as holding an enormous
potential to incubate clusters, and anticipates that the life sciences will take a prominent role in innovation initiatives in
these two countries. Merck is partnering with the Council on Competitiveness in order to bring innovation programs to
the region. The initiative also takes advantage of local partners in both Mexico and Brazil. In addition to these two
countries, exploratory contacts are ongoing in Chile, Colombia, and Costa Rica.
5.7 RULE-SHAPING:MERCK’S COMPETITIVENESS INITIATIVE IN LATIN AMERICA
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In Mexico, the initiative partners with Instituto Mexicano para la Competitividad (IMCO) to support the development
of a vibrant cross-border life sciences sector, which would improve hemispheric competitiveness in the face of
global competition. To date the initiative has established a steering committee of key US and Mexican business,
scientific, and government leaders, conducted a study assessing the regional and national policy environment for
life sciences innovation, and, along with The National Academy of Medicine, launched the annual “Awards on
Innovation in Health and Food” program. In 2007, a new partnership was established with the University of
California at San Diego to explore research capability in the life sciences in four regions of Mexico and link the
scientific communities of these regions with San Diego. The objective is to accelerate patenting, technology
transfer, and business development plans for their own discoveries while improving business links with the San
Diego life science cluster.
In Brazil, Merck works with Movimento Brasil Competitivo (MBC) to promote the improved performance of existing
Brazilian life sciences technology parks, expand the development of a vibrant and globally competitive life sciences
sector, and raise awareness of the value of innovation. The initiative has published two major studies: Competitive
Brazil: An Essay on Brazilian Competitiveness (2005) and Mechanisms of Innovation and Competitiveness: An
Analysis of Brazilian Technology Parks (2006). MBC also collaborated with the World Bank on the Bank’s Doing
Business in Brazil (2006) report, which evaluates current regulations and their impact on facilitating or hindering
business transactions in Brazil.
Following the Brazilian government’s decision to issue a compulsory license for one of Merck’s HIV/AIDS drugs in
April, 2007, the company is now re-evaluating its short-term investment in this area. However, Merck remains
committed to keeping an open dialogue with the government and scientific community in Brazil consistent with its
view as a long-term investor in the country.
Ultimately, the Competitiveness Initiative is designed to fill the critical gap in business operations and innovation that
will lead to expanded economic opportunities in the region. “If we can connect the chain from basic research all the
way to commercialization by teaching local businesses to patent their products, attract venture capital funding, and
market their innovation, then we can fill the gap that’s there right now,” says Caicedo.
Merck has utilized multiple tools to publicize the value of its initiative, including brochures, panels, conferences,
and press releases. Adequate and appropriate communication also plays an important role in positioning Merck as
an expert and leader in promoting local business innovation in Latin America – a light that pharma is not usually
viewed in. Comments Caicedo, “We need to do a lot of communicating about our activities, even during the
process when projects are being formulated. That’s a best practice – to continuously communicate what we’re
doing. It is sometimes even more effective when independent and credible third parties communicate about this
initiative – so we pay attention to that as well.”
Impact Given the long time horizon of the initiative, and its relatively short lifespan to date, substantial results are not yet
available. MSD has won a number of external awards in the countries where it operates, including “Best Company
to Work for,” “Most Admired Company,” and “Most Socially Responsible Company,” but it is difficult to attribute
them directly to any single activity. While direct business impact is still to be determined, the initiative has allowed
Merck to build strategic relationships in the region. For example, discussions about the initiative with local
government officials have allowed the company to highlight some of the other challenges it faces in its operations,
such as registration of its products. “The initiative has allowed us to develop even stronger and more mutually
respectful relationships with policy-makers and other key decision-makers on issues that are important to us, with
an understanding that we want to be long term investors in these countries,” comments Greeley. “Quantifying these
relationships in terms of business impact, however, is always difficult,” he adds.
Recognizing the long time horizon for the initiative, Merck is only beginning to focus on measuring social or
business impact. While the company values the impact its initiative creates, it recognizes that it is too early to
begin impact assessments given that most of the activities have taken place in the last three years.
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The Role of While the partnerships between Merck, the Council on Competitiveness, and the local partners have been very fruitful,
Collaboration the initiative can benefit from the participation and resources of additional multinational corporations, and more
importantly in the long run, from local businesses and venture capitalists. Unfortunately, due to the long-term nature of
the impacts of an initiative like this, securing commitments from others has proven difficult. Many companies are
focused on short-term results and need to see immediate return on investment to balance the cost of participating as
a major player. The company has, however, formed partnerships in Mexico with local businesses that have begun to
contribute to fund the Mexican initiative.
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